Vaxcyte Inc - PCVX STOCK NEWS

Vaxcyte, Inc. (Nasdaq: PCVX) completes enrollment in Phase 2 study for VAX-24, a 24-valent pneumococcal conjugate vaccine. Topline safety, tolerability, and immunogenicity data expected by Q1 2025, followed by booster dose data by end of 2025. VAX-24 aims to cover more serotypes than existing vaccines, addressing the need for broader-spectrum protection against IPD.

Vaxcyte, Inc. (PCVX) completes enrollment in VAX-31 Adult Program Phase 1/2 study and expects topline safety, tolerability, and immunogenicity data in Q3 2024. Successful completion of VAX-24 Phase 2 Adult Program, moving towards Phase 3 readiness. Progress in VAX-24 Infant Phase 2 Study with expected data by Q1 2025. Significant advancements in global commercial manufacturing capacity. The company holds $1.2 billion in cash and investments as of December 31, 2023, with recent net proceeds of $816.5 million. Vaxcyte aims to advance either VAX-24 or VAX-31 into Phase 3 adult clinical program post VAX-31 study readout.

Vaxcyte, Inc. (PCVX) will report Q4 and full-year 2023 financial results on Feb 27, 2024. A conference call and webcast will follow to discuss results and provide a business update.

Vaxcyte, Inc. (PCVX) closed its underwritten public offering of common stock, generating approximately $862.5 million in gross proceeds. The offering included over 12.6 million shares of common stock and pre-funded warrants to purchase additional shares, with joint book-running managers and lead managers overseeing the process. The company filed a shelf registration statement with the SEC, and the final prospectus supplement and accompanying prospectus are available on the SEC's website.

Vaxcyte, Inc. (PCVX) will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on February 8, 2024. The live webcast can be accessed through the Investors & Media section of the Company’s website. A replay will be available for approximately 30 days after the conference.

Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expecting to generate approximately $750.0 million in gross proceeds. The offering includes 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock, with a public offering price of $64.00 per share for common stock and $63.999 per pre-funded warrant. The underwriters have been granted a 30-day option to purchase up to an additional 1,757,812 shares of common stock at the public offering price per share. The offering is expected to close on February 2, 2024, subject to customary closing conditions. BofA Securities, Jefferies, Leerink Partners LLC, Evercore ISI, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering, with BTIG and Needham & Company as lead managers. Vaxcyte has filed a shelf registration statement with the SEC, and a preliminary prospectus supplement and accompanying prospectus have been filed. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities.

Vaxcyte, Inc. (PCVX) has initiated an underwritten public offering of its common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase additional shares. BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering. The company filed a shelf registration statement with the SEC, and a preliminary prospectus supplement will be available on the SEC's website. This press release does not constitute an offer to sell or a solicitation to buy these securities.

Vaxcyte, Inc. (Nasdaq: PCVX) completes enrollment in Phase 1/2 study for VAX-31, a potential best-in-class pneumococcal conjugate vaccine franchise, with topline safety, tolerability, and immunogenicity data expected in Q3 2024. VAX-31 aims to provide coverage for 95% of IPD circulating in the U.S. adult population, addressing a significant public health need.

Vaxcyte, Inc. (Nasdaq: PCVX) appoints Whitney Jones as Chief People Officer to lead human resources strategy and operations, emphasizing a people-first approach to support organizational growth strategies and advance vaccine candidates, including lead pneumococcal conjugate vaccine franchise programs, VAX-24 and VAX-31.